CARTOON

NIZAR
ASST PROFESSOR
ALSHIFA COLLEGE OF PHARMACY

Banned Drugs (10th February 2011)

NOTIFICATION

Banned Drugs (10^th February 2011)

In exercise of the powers conferred by section 26a of the drugs and cosmetics act, 1940(23 0f 1940), the central Govt hereby prohibits the manufacture, sale and distribution of the following drugs with immediate effect, namely

1. Nimesulide formulations for human use in children below 12 years of age.

2. Cisapride and its formulations for human use

3. Phenylpropanolamine and its formulations for human use.

4. Human placental extract and its formulations for human use

5. Sibutramine and its formulations for human use

6. R-sibutramine and its formulations for human use.


DILIP.C
ASST PROF
ALSHIFA COLLEGE OF PHARMACY

ONGOING PROJECTS IN ALSHIFA COLLEGE OF PHARMACY.2010-2011

 ONGOING PROJECTS IN  DEPARTMENT OF PHARMACY PRACTICE,ALSHIFA COLLEGE OF PHARMACY.2010-2011

1.   1.   A comparative study of health related quality of life: short course and self administered drug therapy in tuberculosis.

2.   2.   Development of hospital formulary in tertiary care referral hospital(al-shifa hospital)

3.   3.   Drug  utilization and prescription monitoring of as thematic patients in a secondary level hospital and a tertiary hospital

4.    4. Evaluation and comparison of the efficacy and safety of ferrous fumarate and carbonyl iron in pregnancy induced iron deficiency.

5.    5.  Adverse drug reaction monitoring in tertiary level referral hospital

6.   6.   A comparative study on the effectiveness of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy.

7.   7.   Efficiency of cetyl myristoleate and adjunctive therapy in patients with osteoarthritis.

8.   8.   Evaluation of resistance pattern of bacterial pathogens against commonly used antimicrobial agents in a tertiary care hospital.

9.   9.   Assessment of drug prescribing patterns in dermatology outpatient department in a tertiary care hospital.

The evaluation and comparison of the efficacy and safety of ferrous fumarate and carbonyl iron in pregnancy induced iron deficiency.

The evaluation and comparison of the efficacy and safety

of ferrous fumarate and carbonyl iron in pregnancy

induced iron deficiency.

           Iron deficiency anemia is the commonest medical disorder to occur in pregnant women affecting around 80% of the pregnant females. The objective of the study was to compare the efficacy and tolerability of a marketed formulation containing ferrous fumarate and carbonyl iron in the treatment of pregnancy induced ID. This is a prospective study with a total of 300 pregnant females. And they were randomly assigned into two groups of 150 each and were allocated to receive formulation A, LIVOGEN-Z or formulation B, CARBOFER-Z. The enrolled patients were followed up after every 4 weeks during which their Efficacy evaluation was noted using hemoglobin value and Clinical safety was evaluated based upon the nature and severity of adverse effects. The response and tolerability to therapy was recorded on a 5-point rating scale using PGART and PGATT. The patients were also given counselling, interventional programs leaflets and thank you form during the study period. The rise in hemoglobin in the patients receiving a ferrous fumarate preparation was significantly better than that seen in the patients receiving a carbonyl iron preparation. The adverse reaction was also noted and the ferrous fumarate group showed a significantly better outcome with respect to response to therapy (p<0.0001) as well as tolerability (p=0.002). Ferrous fumarate is not only significantly superior in efficacy but is better tolerated than carbonyl iron. Ferrous fumarate is safe in pregnancy and gives a good hematological response with minimal adverse effects and can be used for the treatment of iron deficiency during pregnancy.

Laigy george

Second M pharm.

Dept of pharmacy practice

Alshifa college of pharmacy

Google

Google